8-K: Pulmonx Reports Strong First Quarter 2025 Financial Results, Driven by Global Zephyr Valve Adoption

Pulmonx Corporation announced a 20% increase in worldwide revenue for Q1 2025, driven by growth in both U.S. and international markets and reaffirms full year 2025 revenue guidance.

Summary

• Pulmonx Corporation reported its financial results for the first quarter of 2025, ended March 31, 2025.
• Worldwide revenue reached $22.5 million, a 20% increase compared to $18.9 million in the first quarter of 2024.
• On a constant currency basis, revenue increased by 21%.
• U.S. revenue was $14.2 million, an 11% increase year-over-year.
• International revenue was $8.3 million, a 39% increase compared to the first quarter of 2024, or 43% on a constant currency basis.
• Gross profit was $16.3 million, compared to $14.1 million in the same period last year.
• Gross margin was 73%, slightly lower than the 75% reported in the first quarter of 2024.
• Operating expenses increased by 8% to $30.9 million, primarily due to increased commercial investments.
• Net loss was $14.4 million, or $0.36 per share, compared to a net loss of $13.7 million, or $0.36 per share, for the same period in 2024.
• Adjusted EBITDA loss was $8.5 million, compared to $8.0 million in the first quarter of 2024.
• Cash, cash equivalents, and marketable securities totaled $88.7 million as of March 31, 2025.
• The company reaffirmed its full-year 2025 revenue guidance of $96 million to $98 million.
• The company expects a full-year 2025 gross margin of approximately 74% and total operating expenses between $133 million and $135 million, including $22 million of non-cash stock-based compensation.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the strong revenue growth, reaffirmed guidance, and resolution of the DOJ inquiry. However, the continued net losses and slight decrease in gross margin temper the overall outlook.

Positives

• Worldwide revenue increased by 20% year-over-year, indicating strong growth.
• International revenue showed significant growth, increasing by 39% (43% on a constant currency basis).
• The company reaffirmed its full-year revenue guidance, suggesting confidence in future performance.
• Amendment of the loan agreement with CIBC Innovation Banking provides financial flexibility by extending the interest-only period.
• The U.S. Department of Justice's decision not to intervene in the case against Pulmonx removes a potential legal overhang.

Negatives

• Gross margin decreased slightly from 75% in Q1 2024 to 73% in Q1 2025.
• Net loss remained significant at $14.4 million, although similar to the previous year's $13.7 million.
• Adjusted EBITDA loss increased slightly from $8.0 million to $8.5 million.
• Operating expenses increased by 8%, primarily due to increased commercial investments.

Risks

• The company's reaffirmed guidance does not reflect potential impacts from future tariffs, trade policy changes, or global macroeconomic conditions, including foreign currency fluctuations.
• Forward-looking statements are subject to risks and uncertainties detailed in Pulmonx's SEC filings, including the Annual Report on Form 10-K.

Future Outlook

Pulmonx reaffirms its full-year 2025 revenue guidance to be in the range of $96 million to $98 million and expects a gross margin of approximately 74%. Total operating expenses for the full year 2025 are expected to fall within the range of $133 million to $135 million, inclusive of approximately $22 million of non-cash stock-based compensation.

Management Comments

• Steve Williamson, President and Chief Executive Officer, stated that Pulmonx is off to a strong start in 2025 and that the company's commercial initiatives underscore the strength of its long-term growth strategy.
• Mr. Williamson believes Pulmonx is well-positioned to deliver sustained growth and create long-term value for shareholders.

Industry Context

Pulmonx operates in the market for minimally invasive treatments for lung disease, specifically COPD and emphysema. The company's performance reflects the increasing adoption of its Zephyr Valve and related technologies in this space.

Comparison to Industry Standards

• It's difficult to provide a precise comparison without knowing the specific growth rates and financial metrics of Pulmonx's direct competitors in the minimally invasive lung disease treatment market.
• However, a 20% revenue growth rate suggests a strong competitive position, especially considering the challenges often associated with medical device adoption and reimbursement.
• Companies like Olympus and Boston Scientific also operate in the broader respiratory device market, but their specific focus and product portfolios differ from Pulmonx.
• A gross margin of 73% is generally healthy for a medical device company, indicating efficient manufacturing and pricing strategies.

Stakeholder Impact

• Shareholders can expect continued growth and potential long-term value creation.
• Patients with severe emphysema/COPD may benefit from increased access to the Zephyr Valve treatment.
• Employees may experience job security and growth opportunities due to the company's expansion.

Key Dates

Keywords

Pulmonx, Zephyr Valve, COPD, Revenue, Financial Results, EBITDA, Gross Margin, Lung Disease